Medicare copays for new Alzheimer's drug could reach $11,500

Medicare copays for new Alzheimer's drug could reach $11,500

The FDA approved Aduhelm earlier this week, and it's already faced its fair share of controversy.

Medicare copays for new Alzheimer's drug could reach $11,500

The FDA approved Aduhelm earlier this week, and it's already faced its fair share of controversy.

Medicare copays for new Alzheimer’s drug could reach $11,500

WASHINGTON (AP) — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.The drug, called Aduhelm, was approved by the Food and Drug Administration this week and quickly sparked controversy over its price-tag and questionable benefits. An FDA adviser called the decision “prob…

Medicare copays for new Alzheimer’s drug could reach $11,500

WASHINGTON (AP) — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, a…

Medicare copays for new Alzheimer’s drug could reach $11,500

An FDA adviser called the decision “probably the worst drug approval decision in recent U.S. history,” in a letter he submitted when resigning over the decision Thursday.

Medicare copays for new Alzheimer’s drug could reach $11,500

By Ricardo Alonso-Zaldivar and Matthew Perrone | Associated PressWASHINGTON — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday.The drug, called Aduhelm, was approved by the Food and Drug Administration this week and quickly sparked controversy over its price-tag and que…